AbbVie (ABBV) Stock

The ProShares S&P 500 Dividend Aristocrat ETF has increased by 10.26% so far this year, as of October. I will share three strategies that could potentially outperform the dividend aristocrat index over time. After monitoring these strategies for 40 months, two of them have shown a compound annual growth rate (CAGR) that is better than NOBL.

Investors seeking to increase their passive income should consider focusing on the pharmaceutical sector. While the S&P 500 index saw an impressive rise of 55.5% from late 2022 to November 22, many companies in the drug industry did not benefit from this growth.

AbbVie's stock fell by 17.3% after the failure of Emraclidine's phase 2 trial, but the company is expected to make up for the loss of Humira's revenue and increase overall sales. By 2027, Skyrizi and Rinvoq are anticipated to exceed Humira's highest earnings, suggesting good growth in the immunology area. The oncology and neuroscience divisions also look promising with recent acquisitions like ImmunoGen and Aliada, even though there have been challenges in developing drugs for schizophrenia.

Leerink Partners has raised its rating for ABBV stock from Market Perform to Outperform.

Dublin, November 25, 2024 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com has included the company profile "Enterprise Tech Ecosystem Series: AbbVie Inc. - 2024" in its collection.

Earlier this month, the S&P 500 reached a historic high of over 6,000 for the first time. Because of this, you might think that stocks are currently too pricey to purchase, as the average stock in the index is valued at more than 25 times its earnings.

Political instability has opened up chances to invest in top healthcare stocks that offer significant dividends. This situation has made these blue-chip companies more attractive to buyers.

In this market, companies that offer high dividend yields are quite rare.

Recently, investors in the financial markets have been negative about AbbVie's future, mainly because of the clinical data on emraclidine. However, I think the market has reacted too strongly to this information, especially considering the rise in dividend payments and the full-year non-GAAP EPS. AbbVie remains a top player in the global immunology market, largely due to the success of its two key products, Skyrizi and Rinvoq.